Live
CellThermodynamic prediction of RNA cellular activity from sequence via conformational ensemblesCellContextual computation by competitive protein dimerization networksCellTransplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease modelsFierceBiotechPfizer adds to Seagen scrap heap with another early cancer candidate cullFierceBiotechGenentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failureScienceDebate explodes over age of key South American archaeological siteScienceWhat happened when an Arab neuroscientist took the helm at an Israeli university?BioPharma DiveNovo uses FDA voucher to win speedy approval of higher-dose WegovyEndpoints NewsNovo wins FDA approval for high-dose Wegovy under commissioner's voucherEndpoints NewsVerily raises $300M, sheds Alphabet’s majority controlEndpoints NewsTerraPower’s $450M radioisotope factory; Lilly’s $126M Japan budgetIlluminaILMN Stock Gains Following Expanded Collaboration With Labcorp - Yahoo! Finance Canada
Roche Media Jan 27, 2026

Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech

Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech

Original
Body unavailable. Use the original source.

Directory

59 All